Streetbeat News

PLSE

Pulse Biosciences, Inc.

https://www.pulsebiosciences.com

Industry

Medical - Instruments & Supplies

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Open

16.27

Mkt cap

1.1B

Volume

138K

High

17.71

P/E Ratio

-21.30

52-wk high

22.69

Low

16.05

Div yield

N/A

52-wk low

6.59

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Athira Pharma, ChromaDex, and Theriva Biologics, while Lexicon Pharmaceuticals and Myriad Genetics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 4:36 pm

Pulse Biosciences shares declined following the announcement of a year-over-year decrease in Q3 EPS results.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:51 pm

Pulse Biosciences announced positive results from a European feasibility study using its nano-PFA technology to treat benign thyroid nodules, showing over 50% reduction in nodule volume and symptomatic relief within a month.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:26 pm

Pulse Biosciences reported a Q3 EPS loss of $(0.21), a 40% increase in losses compared to $(0.15) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:53 pm

Loar Holdings Inc. (NYSE:LOAR) reported better-than-expected second-quarter earnings and sales, leading to an 18.2% increase in its stock price. Other notable gainers include iLearningEngines, Inc. (NASDAQ:AILE), Starbucks Corporation (NASDAQ:SBUX), PACS Group, Inc. (NYSE:PACS), Pulse Biosciences, Inc. (NASDAQ:PLSE), and Clean Energy Fuels Corp. (NASDAQ:CLNE), among others.

Portfolio Pulse from Avi Kapoor

August 13, 2024 | 3:44 pm

Pulse Biosciences has appointed Paul LaViolette as Co-Chairman, joining Robert W. Duggan in the role. This leadership change could influence the company's strategic direction and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:02 pm

Pulse Biosciences has announced the treatment of the first two patients in a first-in-human feasibility study using its Nano-PFA Cardiac Surgery System for atrial fibrillation. The system is also enrolled in the FDA's Total Product Life Cycle Advisory Program.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:35 pm

Pulse Biosciences has received FDA Breakthrough Device Designation for its cardiac surgery system that uses nanosecond pulsed field ablation technology to treat atrial fibrillation.

Portfolio Pulse from Benzinga Newsdesk

July 08, 2024 | 12:02 pm

Pulse Biosciences announced preliminary results for its rights offering, expected to generate $60M in immediate gross proceeds. The offering received subscriptions exceeding $83M, with allocations to be proportionately distributed among over-subscribed rights holders. The company expects to receive $60M in gross proceeds, with potential additional proceeds from warrant exercises.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:05 pm

Pulse Biosciences, Inc. (NASDAQ:PLSE) has commenced a rights offering of up to $60 million of units. The subscription rights will expire on June 26, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 12:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.